Biotech Values

[mcbio]

EPIX/TKAI

Very interesting company. Only real shot I know of (outside IO) for a treatment of Xtandi/Zytiga failures. I have a modest personal position bought (on Canadian exchange) quite a while back.

How do you compare what EPIX is doing to TKAI, which is much further ahead as already in a pivotal P3 trial with PFS (not OS) as primary endpoint: http://investors.tokaipharma.com/phoenix.zhtml?c=252857&p=irol-newsArticle&ID=2062108 ? Both companies are specifically targeting Xtandi/Zytiga failures albeit what I think are different MoA.

I think the one big caveat on TKAI is that the P2 data in ARV7 patients specifically was of an ad hoc nature and there is some debate at least on whether the patients truly were ARV7 patients. On the other hand, valuation is pretty cheap at ~$300M market cap (barely above EPIX market cap and their drug is just getting ready to enter clinic) and data for Xtandi/Zytiga in this patient population is very poor. So, if TKAI drug truly works in this setting, would seem to be a reasonable risk-reward here. No position in either TKAI or EPIX but both have been on my watch list now for awhile.